Acute promyelocytic leukemia as a paradigm for targeted therapy

Seminars in Hematology

Volumn 41, Issue 2 SUPPL. 4, 2004, Pages 27-32

  Tallman, Martin S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOMYCIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; DRUG MECHANISM; DRUG TARGETING; HUMAN; LEUKEMIA REMISSION; LEUKEMOGENESIS; MOLECULAR GENETICS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RELAPSE; REVIEW; STEM CELL TRANSPLANTATION;

EID: 2442533724     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2004.02.004     Document Type: Article

References (41)

1. Parmar S, Tallman MS: Acute promyelocytic leukaemia: A review. Expert Opin Pharmacother 4:1379-1392, 2003
2. Slack JL, Waxman S, Tricot G, et al: Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist 1:1-13, 2002 (suppl)
3. Tallman MS, Nabhan C: Management of acute promyelocytic leukemia. Curr Oncol Rep 4:381-389, 2002
4. Paietta E, Andersen J, Racevskis J, et al: Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses. Leukemia 8:968-973, 1994
5. Michieli M, Damiani D, Ermacora A, et al: P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia. Br J Haematol 108:703-709, 2000
6. Grignani F, De Matteis S, Nervi C, et al: Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815-818, 1998
7. Diverio D, Rossi V, Avvisati G, et al: Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood 92:784-789, 1998
8. Gallagher RE, Yeap BY, Bi W, et al: Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from Intergroup protocol 0129. Blood 101: 2521-2528, 2003
9. Lo Coco F, Diverio D, Falini B, et al: Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 94:12-22, 1999
10. Liu TX, Zhang JW, Tao J, et al: Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 96:1496-1504, 2000
11. Gianni M, Ponzanelli I, Mologni L, et al: Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells: Expression and activation of caspases. Cell Death Differ 7:447-460, 2000
12. Dombret H, Fenaux P, Soignet SL, et al: Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 39:8-13, 2002
13. Fenaux P, Chevret S, Guerci A, et al: Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia: European APL group. Leukemia 14:1371-1377, 2000
14. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100:4298-4302, 2002
15. Sanz MA, Lo CF, Martin G, et al: Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247-1253, 2000
16. Sanz MA, Martin G, Gonzalez M, et al: Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA Group. Blood e-pub on-line 2003
17. Fenaux P, Chastang C, Chevret S, et al: A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: The European APL Group. Blood 94:1192-1200, 1999
18. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021-1028, 1997
19. Burnett AK, Grimwade D, Solomon E, et al: Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial. Blood 93:4131-4143, 1999
20. Tallman MS, Nabhan C, Feusner JH, et al: Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99:759-767, 2002
21. Sanz MA, Martin G, Rayon C, et al: A modified AIDA protocol with anthracycline-based consolidation results in high anti-leukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia: PETHEMA group. Blood 94:3015-3021, 1999
22. Avvisati G, Petti MC, Lo Coco F, et al: AIDA: The Italian way of treating acute promyelocytic leukemia (APL), final act. Blood 102:142, 2003 (abstr)
23. Miller WH Jr, Schipper HM, Lee JS, et al: Mechanisms of action of arsenic trioxide. Cancer Res 62:3893-3903, 2002
24. 3 exerts dose-dependent dual effects on APL cells. Blood 89:3345-3353, 1997
25. Niu C, Yan H, Yu T, et al: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94:3315-3324, 1999
26. Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348, 1998
27. Soignet SL, Frankel SR, Douer D, et al: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852-3860, 2001
28. Ohnishi K, Yoshida H, Shigeno K, et al: Arsenic trioxide therapy for relapsed or refractoryJapanese patients with acute promyelocytic leukemia: Need for careful electrocardiogram monitoring. Leukemia 16:617-622, 2002
29. Shen Y, Shen ZX, Yan H, et al: Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: A comparison with conventional dosage. Leukemia 15:735-741, 2001
30. 3) in the treatment of patients with acute promyelocytic leukemia: The M.D. Anderson experience. Cancer 97:2218-2224, 2003
31. Douer D, Hu W, Giralt S, et al: Arsenic trioxide (Trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 8:132-140, 2003
32. Lo Coco F, Diverio D, Avvisati G, et al: Therapy of molecular relapse in acute promyelocytic leukemia. Blood 94:2225-2229, 1999
33. Raffoux E, Rousselot P, Poupon J, et al: Combined treatment with arsenic trioxide and all-trans retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21:2326-2334, 2003
34. Estey EH: Treatment options for relapsed acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16:521-534, 2003
35. Estey EH, Faderl S, Giles F, et al: All-trans retinoic acid (ATRA) + arsenic trioxide (ATO) to minimize or eliminate chemotherapy in untreated APL. Blood 102:618a-619, 2003 (abstr)
36. Mulford DA, Maslak PG, Weiss MA, et al: Reducing standard postremission chemotherapy in acute promyelocytic leukemia (APL) with risk-adapted therapy. Blood 102:619a-620, 2003 (abstr)
37. 3 combination yields a high-quality clinical/molecular remission and disease-free survival in newly diagnosed patients with acute promyelocytic leukemia. Blood 102:141-142, 2003 (abstr)
38. 3). Blood 102:620, 2003 (abstr)
39. Lu DP, Qiu JY, Jiang B, et al: Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 99:3136-3143, 2002
40. Douer D, Estey E, Santillana S, et al: Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood 97:73-80, 2001
41. Estey EH, Giles FJ, Beran M, et al: Experience with gemtuzumab ozogamycin («mylotarg») and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 99:4222-4224, 2002